Stockscreener 앱 받기
1.12
0.88%
-0.010
시간 외 거래:
1.12
전일 마감가:
$1.13
열려 있는:
$1.13
하루 거래량:
757.15K
Relative Volume:
1.56
시가총액:
$69.35M
수익:
$248.00K
순이익/손실:
$-113.22M
주가수익비율:
-0.6082
EPS:
-1.8416
순현금흐름:
$-98.81M
1주 성능:
-4.27%
1개월 성능:
-3.45%
6개월 성능:
-15.15%
1년 성능:
-20.00%
1일 변동 폭
$1.105
$1.15
1주일 범위
$1.105
$1.18
52주 변동 폭
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.12 | 69.97M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 재개 | Cantor Fitzgerald | Neutral |
| 2025-03-04 | 다운그레이드 | Needham | Buy → Hold |
| 2025-03-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-02-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Price to earnings forward of Pliant Therapeutics, Inc. – TRADEGATE:9PT - TradingView
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – GETTEX:9PT - TradingView
PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
9PT Forecast — Price Target — Prediction for 2027 - TradingView
Pliant Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLRX) - TradingView
PLRX Forecast — Price Target — Prediction for 2027 - TradingView
Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics Inc (PLRX) Institutional Confidence - TradingKey
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14 - Stock Titan
PLIANT THERAPEUTICS (PLRX) director granted 70,000 stock options at $1.14 - Stock Titan
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Pliant Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) reports 2026 director, pay and auditor votes - Stock Titan
PLIANT THERAPEUTICS INC (PLRX) Stock Chart - ChartMill
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - The Manila Times
Primary Sclerosing Cholangitis Market is Projected to Boom by 2034 Owing to the Launch of Novel Therapies | DelveInsight - Barchart
Pliant Therapeutics (PLRX) Inches Higher: Consolidation Near Support Amid Biotech Sector VolatilityAccumulation Line - newsline.com
PLRXPliant Therapeutics Inc Stock Price and Quote - Finviz
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains, Biotech Sector Weakness PersistsNAAIM Leverage - The Legal Advocate
Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference - Bez Kabli
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains – Key Levels in FocusCumulative Volume - The Legal Advocate
Pliant Therapeutics (PLRX) Edges Higher as Stock Holds Above Key SupportNHNL Ratio - The Legal Advocate
Pliant Therapeutics (PLRX) Faces Selling Pressure, Testing Key Support at $1.15Revenue Growth Stocks - newsline.com
Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang
Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com
Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union
Pliant Drug Aims to Break Cancer's Resistance to Immunotherapy - BriefGlance
Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan
Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pliant Therapeutics (PLRX) Delivers Q1 2026 Beat — EPS $-0.32 vs $-0.36 ExpectedEPS Guidance Update - The Legal Advocate
Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan
Pliant Therapeutics (PLRX) Stock Price, Quote, Charts & News - Invezz
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board – Company AnnouncementFT.com - Financial Times
TradingKey - TradingKey
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pliant Therapeutics Inc 주식 (PLRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
2.64%
자본화:
|
볼륨(24시간):